Compare MasTec Inc (MTZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MasTec Inc trades at $212.74 (market cap $17.40B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× MasTec Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MTZ | VRTX | |
|---|---|---|
Market Cap | $17.40B | $127.55B |
Volume | 1,415,821 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $437.51 | $557.96 |
52-Week Low | $190.08 | $407.37 |
Typical Hold Time | 23 Days | 120 Days |
Enterprise Value | $20.32B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $214.84, down 3.82% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but a Q2 2026 miss, while fundamentals reveal solid revenue growth and profitability metrics. The company benefits from record backlog and infrastructure demand, particularly in power delivery and data center markets.
MTZ presents a compelling long-term opportunity with 89% analyst buy ratings and a $408.58 consensus target, though premium valuation and weak cash flow pose risks. Infrastructure spending tailwinds and AI-driven demand support growth, but execution challenges and communications segment softness require monitoring.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
